BioCentury | Nov 30, 2017
Clinical News

Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

...In September, Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) reported additional data from 6 patients with moderate to severe bullous...
...QOL) score. Bertilimumab is a human mAb against chemokine CC motif ligand 11 (CCL11; eotaxin-1). Immune Pharmaceuticals...
...degeneration (AMD). AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc....
BioCentury | Nov 3, 2017
Financial News

Immune Pharma raises $18M in follow-on

...On Oct. 19, immunology and inflammation company Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) raised $18 million through the sale...
...preferred stock and 982 seven-year warrants to purchase a share of common stock at $1.10. Immune Pharmaceuticals Inc....
BioCentury | Aug 15, 2017
Company News

Management tracks: Cerecor, Allakos, Epizyme, Merrimack

...and movement disorders at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Autoimmune and cancer company Immune Pharmaceuticals Inc....
BioCentury | Jul 14, 2017
Clinical News

Immune begins Phase I/II of Ceplene in CMML

...EU and Israel for maintenance of remission and prevention of relapse in patients with AML. Immune Pharmaceuticals Inc....
...OS) and circulating CD8+ and CD4+ T cells Status: Phase I/II started Milestone: NA Alex Himes Ceplene histamine dihydrochloride Immune Pharmaceuticals Inc. histamine...
BioCentury | Mar 17, 2017
Clinical News

Bertilimumab: Preliminary Ph II data

...the patients' oral prednisone dose was tapered down to ≤10 mg/day. Based on the data, Immune Pharmaceuticals...
...off of chronic steroids. Bullous pemphigoid is a rare autoimmune blistering disease of the skin. Immune Pharmaceuticals...
...ocular allergies and wet age-related macular degeneration (AMD). iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc....
BioCentury | Jan 27, 2017
Company News

SATT Sud-Est, Immune Pharmaceuticals deal

...to inquiries. SATT Sud-Est, Marseille, France Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), New York, N.Y. Business: Cancer, Antibodies Alex Himes Immune Pharmaceuticals Inc. Interleukin-8...
BioCentury | Nov 18, 2016
Financial News

Immune Pharmaceuticals completes private placement of convertible notes

...up to an additional $10 million from the investor. Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), New York, N.Y. Alex Himes Immune Pharmaceuticals Inc....
BioCentury | Sep 26, 2016
Financial News

Immune Pharmaceuticals proposes private placement

...Shares: TBD Price prior: $0.34 Shares outstanding prior: 101.6 million Investor: Novel Pain Therapeutics Note: Immune Pharmaceuticals...
BioCentury | Sep 12, 2016
Emerging Company Profile

Age factors

...models to treat AD and other age-related disorders. McCracken would not disclose a development timeline. Immune Pharmaceuticals...
...Carlos, Calif. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), Barcelona, Spain iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc....
BioCentury | Sep 12, 2016
Financial News

Immune Pharmaceuticals completes private placement

Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), New York, N.Y. Business: Cancer, Neurology, Autoimmune Date completed: 2016-09-07 Type: Private placement Raised: $2 million Shares: 4 million Price: $0.50 Shares after offering: 101.6 million Investor: Existing investor WIR...
Items per page:
1 - 10 of 45
BioCentury | Nov 30, 2017
Clinical News

Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

...In September, Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) reported additional data from 6 patients with moderate to severe bullous...
...QOL) score. Bertilimumab is a human mAb against chemokine CC motif ligand 11 (CCL11; eotaxin-1). Immune Pharmaceuticals...
...degeneration (AMD). AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc....
BioCentury | Nov 3, 2017
Financial News

Immune Pharma raises $18M in follow-on

...On Oct. 19, immunology and inflammation company Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) raised $18 million through the sale...
...preferred stock and 982 seven-year warrants to purchase a share of common stock at $1.10. Immune Pharmaceuticals Inc....
BioCentury | Aug 15, 2017
Company News

Management tracks: Cerecor, Allakos, Epizyme, Merrimack

...and movement disorders at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Autoimmune and cancer company Immune Pharmaceuticals Inc....
BioCentury | Jul 14, 2017
Clinical News

Immune begins Phase I/II of Ceplene in CMML

...EU and Israel for maintenance of remission and prevention of relapse in patients with AML. Immune Pharmaceuticals Inc....
...OS) and circulating CD8+ and CD4+ T cells Status: Phase I/II started Milestone: NA Alex Himes Ceplene histamine dihydrochloride Immune Pharmaceuticals Inc. histamine...
BioCentury | Mar 17, 2017
Clinical News

Bertilimumab: Preliminary Ph II data

...the patients' oral prednisone dose was tapered down to ≤10 mg/day. Based on the data, Immune Pharmaceuticals...
...off of chronic steroids. Bullous pemphigoid is a rare autoimmune blistering disease of the skin. Immune Pharmaceuticals...
...ocular allergies and wet age-related macular degeneration (AMD). iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc....
BioCentury | Jan 27, 2017
Company News

SATT Sud-Est, Immune Pharmaceuticals deal

...to inquiries. SATT Sud-Est, Marseille, France Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), New York, N.Y. Business: Cancer, Antibodies Alex Himes Immune Pharmaceuticals Inc. Interleukin-8...
BioCentury | Nov 18, 2016
Financial News

Immune Pharmaceuticals completes private placement of convertible notes

...up to an additional $10 million from the investor. Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), New York, N.Y. Alex Himes Immune Pharmaceuticals Inc....
BioCentury | Sep 26, 2016
Financial News

Immune Pharmaceuticals proposes private placement

...Shares: TBD Price prior: $0.34 Shares outstanding prior: 101.6 million Investor: Novel Pain Therapeutics Note: Immune Pharmaceuticals...
BioCentury | Sep 12, 2016
Emerging Company Profile

Age factors

...models to treat AD and other age-related disorders. McCracken would not disclose a development timeline. Immune Pharmaceuticals...
...Carlos, Calif. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), Barcelona, Spain iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc....
BioCentury | Sep 12, 2016
Financial News

Immune Pharmaceuticals completes private placement

Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), New York, N.Y. Business: Cancer, Neurology, Autoimmune Date completed: 2016-09-07 Type: Private placement Raised: $2 million Shares: 4 million Price: $0.50 Shares after offering: 101.6 million Investor: Existing investor WIR...
Items per page:
1 - 10 of 45